MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
1. MaxCyte partners with Ori Biotech to enhance cell therapy manufacturing. 2. Collaboration aims to improve efficiency and yield of gene-edited T cells. 3. MaxCyte's ExPERT™ platform integrates with Ori's IRO® for better scalability. 4. Joint efforts focus on CD19 CAR expression in activated T cells. 5. Partnership may accelerate availability of transformative cell therapies.